)
In a nutshell
This article presents the results of a phase III clinical trial that evaluated the safety and efficacy of Toremifene (Acapodene) for lowering fracture risk in men with prostate cancer receiving androgen deprivation therapy (ADT). The risk of spinal fractures was significantly reduced in patients who received Toremifene.
Some background
Prostate cancer is fueled by the male hormone testosterone and its related hormones together called androgens. Hormone therapy (also called androgen deprivation therapy or ADT) is used to stop the production of male hormones, thus stopping the growth of the cancer. However, men treated with ADT are at increased risk of developing osteoporosis. This leads to brittle bones and a higher risk of fractures, especially in the spine or hips. Toremifene is a new drug that has been proven effective in reducing the risk of fractures in men with prostate cancer treated with ADT.
Methods & findings
The bottom line
In summary, toremifene significantly reduced the risk of spine fractures in men with prostate cancer treated with ADT. Additionally, toremifene lowered the risk of osteoporosis and cholesterol levels.
The fine print
Toremifene is not yet approved by the FDA for the prevention of bone fractures in men with prostate cancer treated with ADT.
This clinical trial was funded by GTx, Inc., the manufacturer of toremifene.
Published By :
Journal of Urology
Date :
Jan 01, 2013
